Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical […]
Maris-Tech Receives Repeat Order for Approximately $600,000 with an Option to Increase to Approximately $730,000 from a Company in the Defense Industry for its Unique Situational Awareness Solution
Total orders for the innovative, customized system from this customer climb to approximately $1,287,000 Rehovot, Israel, Feb. 21, 2024 (GLOBE […]
Brera Holdings’ Strategic Victory: A Leap Forward for Mozambique, Brera Tchumene FC and Global ESG Ambitions
DUBLIN, Ireland and Milan, Italy, Feb. 21, 2024 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) […]
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), […]
Baker Hughes Secures Major Multi-Year Well Construction Services Contract with Petrobras
Company to provide well construction services in Buzios field offshore Brazil Positions Baker Hughes as integrated solutions supplier for Petrobras […]
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering […]
European Wax Center, Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on March 6th
PLANO, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) — European Wax Center, Inc. (NASDAQ: EWCZ), the largest and fastest-growing franchisor and […]
CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for […]
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of […]
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
– Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD – Poster […]
